Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Only a few months after Medtronic completed its acquisition of cardiac device maker Affera, the nearly billion-dollar buyout is already paying off. A dual-use catheter originally developed by Affera ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.

More than two million Americans struggle with atrial fibrillation. Atrial fibrillation, or AFib, is one of the most common heart rhythm disorders. But treatment only works about half the time. Now, ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Acutus CEO Randy Werneth said in a statement that the information this device gives should allow physicians to offer precise treatment and monitor therapy progress more efficiently.

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for patients with atrial fibrillation (AFib). The approval follows earlier CE ...

Using Rhythm AI Ltd.'s stochastic trajectory analysis of ranked signals (STAR) mapping system with pulmonary vein isolation terminated and eliminated recurrence of persistent atrial fibrillation (AF) ...

Please provide your email address to receive an email when new articles are posted on . Acutus Medical announced that its suite of new algorithms for the mapping and ablation of complex atrial ...

It’s a good time to enter the EP-mapping and ablation device market, as Millennium Research Group reports, the more and more popular A-fib ablation procedure will drive those areas toward a value of ...

MIAMI. (Ivanhoe Newswire) – Atrial fibrillation, or AFib, is one of the most common heart rhythm disorders. But treatment only works about half the time. Now, that may be about to change, thanks to a ...